BTN3A2 and ovarian carcinoma: To better understand the role of BT3.2 in ovarian cancer and more particularly to confirm our observed association of mRNA BT3.2 expression with a good patient prognosis [5], we performed an immunohistochemistry analysis of BT3.2 protein expression on a large cohort of 199 high grade serous EOC patients and confirmed the association of BT3.2 and prognosis of EOC patients.